JP2022526525A5 - - Google Patents

Info

Publication number
JP2022526525A5
JP2022526525A5 JP2021557187A JP2021557187A JP2022526525A5 JP 2022526525 A5 JP2022526525 A5 JP 2022526525A5 JP 2021557187 A JP2021557187 A JP 2021557187A JP 2021557187 A JP2021557187 A JP 2021557187A JP 2022526525 A5 JP2022526525 A5 JP 2022526525A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
inhibitor
cancer
composition according
combination
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021557187A
Other languages
English (en)
Japanese (ja)
Other versions
JP7824627B2 (ja
JP2022526525A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2020/058362 external-priority patent/WO2020193631A1/en
Publication of JP2022526525A publication Critical patent/JP2022526525A/ja
Publication of JP2022526525A5 publication Critical patent/JP2022526525A5/ja
Priority to JP2026021790A priority Critical patent/JP2026077769A/ja
Application granted granted Critical
Publication of JP7824627B2 publication Critical patent/JP7824627B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021557187A 2019-03-25 2020-03-25 癌療法のためのイアダデムスタット(iadademstat)の組み合わせ物 Active JP7824627B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2026021790A JP2026077769A (ja) 2019-03-25 2026-02-13 癌療法のためのイアダデムスタット(iadademstat)の組み合わせ物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP19382206 2019-03-25
EP19382206.1 2019-03-25
PCT/EP2020/058362 WO2020193631A1 (en) 2019-03-25 2020-03-25 Combinations of iadademstat for cancer therapy

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2026021790A Division JP2026077769A (ja) 2019-03-25 2026-02-13 癌療法のためのイアダデムスタット(iadademstat)の組み合わせ物

Publications (3)

Publication Number Publication Date
JP2022526525A JP2022526525A (ja) 2022-05-25
JP2022526525A5 true JP2022526525A5 (cg-RX-API-DMAC10.html) 2023-04-04
JP7824627B2 JP7824627B2 (ja) 2026-03-05

Family

ID=66175363

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021557187A Active JP7824627B2 (ja) 2019-03-25 2020-03-25 癌療法のためのイアダデムスタット(iadademstat)の組み合わせ物
JP2026021790A Withdrawn JP2026077769A (ja) 2019-03-25 2026-02-13 癌療法のためのイアダデムスタット(iadademstat)の組み合わせ物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2026021790A Withdrawn JP2026077769A (ja) 2019-03-25 2026-02-13 癌療法のためのイアダデムスタット(iadademstat)の組み合わせ物

Country Status (13)

Country Link
US (1) US20220175698A1 (cg-RX-API-DMAC10.html)
EP (1) EP3946295B1 (cg-RX-API-DMAC10.html)
JP (2) JP7824627B2 (cg-RX-API-DMAC10.html)
KR (1) KR20210142614A (cg-RX-API-DMAC10.html)
CN (2) CN113573702A (cg-RX-API-DMAC10.html)
AU (1) AU2020249493B2 (cg-RX-API-DMAC10.html)
BR (1) BR112021016171A2 (cg-RX-API-DMAC10.html)
CA (1) CA3132473A1 (cg-RX-API-DMAC10.html)
IL (1) IL286353A (cg-RX-API-DMAC10.html)
MX (1) MX2021011610A (cg-RX-API-DMAC10.html)
PH (1) PH12021552326A1 (cg-RX-API-DMAC10.html)
SG (1) SG11202109025XA (cg-RX-API-DMAC10.html)
WO (1) WO2020193631A1 (cg-RX-API-DMAC10.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201913290QA (en) 2016-03-15 2020-03-30 Oryzon Genomics Sa Combinations of lsd1 inhibitors for the treatment of hematological malignancies
SI3941466T1 (sl) 2019-03-20 2026-04-30 Oryzon Genomics, S.A. Vafidemstat za zdravljenje neagresivnih simptomov mejne osebnostne motnje

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9469597B2 (en) 2011-10-20 2016-10-18 Oryzon Genomics S.A. (Hetero)aryl cyclopropylamine compounds as LSD1 inhibitors
EP3090998A1 (en) 2015-05-06 2016-11-09 F. Hoffmann-La Roche AG Solid forms
CN120661674A (zh) 2016-03-15 2025-09-19 奥莱松基因组股份有限公司 用于治疗实体瘤的lsd1抑制剂的组合
US20190256929A1 (en) * 2016-11-03 2019-08-22 Oryzon Genomics, S.A. Pharmacodynamic biomarkers for personalized cancer care using epigenetic modifying agents
US11685782B2 (en) * 2017-10-23 2023-06-27 Children's Medical Center Corporation Methods of treating cancer using LSD1 inhibitors in combination with immunotherapy

Similar Documents

Publication Publication Date Title
JP5579715B2 (ja) cdk阻害剤および抗悪性腫瘍剤を含む治療用組合せ
JP2022124458A5 (cg-RX-API-DMAC10.html)
TWI594986B (zh) Antineoplastic agent effect enhancer
TWI641374B (zh) 含低用量伊立替康鹽酸鹽水合物之抗腫瘤劑
JP2019516733A5 (cg-RX-API-DMAC10.html)
JP2016533379A5 (cg-RX-API-DMAC10.html)
EP2501385B1 (en) Therapeutic combination comprising a cdc7 inhibitor and an antineoplastic agent
JP2019508440A5 (cg-RX-API-DMAC10.html)
JP2016535756A5 (cg-RX-API-DMAC10.html)
JP2006524246A5 (cg-RX-API-DMAC10.html)
EP2043640A2 (en) Ccr5 antagonist for enhancing immune reconstitution and treating opportunistic infection in hiv patients
JP2023522716A5 (cg-RX-API-DMAC10.html)
JP2018516936A5 (cg-RX-API-DMAC10.html)
JP2014512355A5 (cg-RX-API-DMAC10.html)
JP2024515809A5 (cg-RX-API-DMAC10.html)
JP2020521786A5 (cg-RX-API-DMAC10.html)
JP2016502540A5 (cg-RX-API-DMAC10.html)
CN110522753A (zh) 一种新型抗肿瘤药物组合物、制剂和应用
JP2024538719A5 (cg-RX-API-DMAC10.html)
JPWO2004081012A1 (ja) 抗腫瘍効果増強剤及び抗腫瘍剤
WO2018068769A1 (zh) 二氢小檗碱型化合物在制备治疗stat3信号通路相关肿瘤疾病产品中的用途
JP2015510945A5 (cg-RX-API-DMAC10.html)
WO2025033367A1 (ja) 抗腫瘍剤併用療法
CN102105148B (zh) 包含aurora激酶抑制剂和抗肿瘤药的治疗组合
CN102105147B (zh) 包含aurora激酶抑制剂和抗肿瘤药的治疗组合